Review
OSI-461 (OSI)
Affiliations
- PMID: 15242254
Item in Clipboard
Review
OSI-461 (OSI)
Curr Opin Investig Drugs.
2004 Jun.
Abstract
OSI Pharmaceuticals is developing OSI-461, a potent analog of exisulind, for the potential treatment of cancer and inflammatory bowel disease. In August 2001, OSI-461 entered phase II trials involving patients with chronic lymphocytic leukemia. In July 2002, the company embarked on a pilot phase II study evaluating OSI-461 for the treatment of Crohn's disease. By October 2002, Cell Pathways had selected hormone-refractory prostate cancer as the lead cancer indication for clinical development of OSI-461.
Similar articles
-
Exisulind Cell Pathways.Curr Opin Investig Drugs. 2000 Nov;1(3):386-91. Curr Opin Investig Drugs. 2000. PMID: 11249724 Review.
-
Epothilone D (Kosan/Roche).Curr Opin Investig Drugs. 2004 Jun;5(6):657-67. Curr Opin Investig Drugs. 2004. PMID: 15242255 Review.
-
Exisulind: Aptosyn, FGN 1, Prevatac, sulindac sulfone.Drugs R D. 2004;5(4):220-6. doi: 10.2165/00126839-200405040-00007. Drugs R D. 2004. PMID: 15230629 Review.
-
AN-9 (Titan).Curr Opin Investig Drugs. 2004 Jun;5(6):628-34. Curr Opin Investig Drugs. 2004. PMID: 15242252 Review.
-
CC-5013 (Celgene).Curr Opin Investig Drugs. 2004 Jun;5(6):635-47. Curr Opin Investig Drugs. 2004. PMID: 15242253 Review.